Efficacy of Ozurdex in DME in the real world clinical setting-Leowenstein interview

Article

Professor Anat Lowenstein talks about the impact of Ozurdex in treating diabetic macular edema (DME) in the real world clinical setting. This renowned expert in the DME field, explores what the licensing of Ozurdex in DME means to both patients and retinal specialists when treating this potentially blinding condition.

Redirect to video article  

 

Recent Videos
1 KOL featured in this series.
1 KOL featured in this series.
1 KOL featured in this series.
1 KOL featured in this series.
Related Content
Trinity team’s gene therapy offers promise for treating glaucoma – as well as AMD

Trinity team’s gene therapy offers promise for treating glaucoma – as well as AMD

Article
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy

Podcast
Formosa Pharmaceuticals makes first shipment of APP13007 to US for commercialization

Formosa Pharmaceuticals makes first shipment of APP13007 to US for commercialization

Article
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Advancing the optimal diagnosis & treatment of thyroid eye disease

Podcast
FDA confirms acceptability of Palatin's remaining Phase 3 pivotal clinical trials for PL9643 in DED

FDA confirms acceptability of Palatin's remaining Phase 3 pivotal clinical trials for PL9643 in DED

Article
Researchers detail acute angle closure glaucoma attack in patient with Hermansky-Pudlak syndrome

Researchers detail acute angle closure glaucoma attack in patient with Hermansky-Pudlak syndrome

Article
© 2024 MJH Life Sciences

All rights reserved.